Proton pump inhibitors on pancreatic cancer risk and survival

详细信息    查看全文

• 作者：Malcolm D. Kearns^a ; ^{malcolmdkearns@gmail.com} ; Ben Boursi^c ; ^d ; ^e ; ^f ; ^{bben217@gmail.com} ; Yu-Xiao Yang^b ; ^c ; ^d ; ^{yangy@mail.med.upenn.edu}
• 关键词：Pancreatic cancer ; Proton pump inhibitors ; Risk ; Survival
• 刊名：Cancer Epidemiology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：46
• 期：Complete
• 页码：80-84
• 全文大小：311 K
• 卷排序：46

文摘

Hypergastrinemia is mechanistically linked to pancreatic cancer risk. Proton pump inhibitors (PPIs) cause hypergastrinemia. PPIs may be associated with an increased risk of pancreatic cancer. PPI use is not associated with survival in pancreatic cancer patients. PPIs should be prescribed judiciously but not withheld in patients with pancreatic cancer.